|
Bravo-Perez C, Sola M, Teruel-Montoya R, Garcia-Malo MD, Ortuno FJ, Vicente V, de Arriba F, Jerez A. Minimal Residual Disease in Multiple Myeloma: Something Old, Something New. Cancers (Basel). 2021 Aug 27;13(17):4332. doi: 10.3390/cancers13174332. PubMed PMID: 34503142; PubMed Central PMCID: PMC8430644.
AÑO: 2021; IF: 6.575
|
34503142
|
Alameda D, Goicoechea I, Vicari M, Arriazu E, Nevone A, Rodriguez S, Lasa M, Puig N, Cedena MT, Alignani D, Garate S, Lara-Astiaso D, Vilas-Zornoza A, Sarvide S, Ocio EM, Lecumberri R, Garcia de Coca A, Labrador J, Gonzalez ME, Palomera L, Gironella M, Cabanas V, Casanova M, Oriol A, Krsnik I, Perez-Montana A, de la Rubia J, de la Puerta JE, de Arriba F, Fazio VM, Martinez-Lopez J, Lahuerta JJ, Mateos MV, Odero MD, Prosper F, Weiner A, Amit I, Nuvolone M, San Miguel JF, Paiva B. Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development. Blood. 2021 Oct 28;138(17):1583-1589. doi: 10.1182/blood.2020009754. PubMed PMID: 34133718.
AÑO: 2021; IF: 25.476
|
|
Puig N, Hernandez MT, Rosinol L, Gonzalez E, de Arriba F, Oriol A, Gonzalez-Calle V, Escalante F, de la Rubia J, Gironella M, Rios R, Garcia-Sanchez R, Arguinano JM, Alegre A, Martin J, Gutierrez NC, Calasanz MJ, Martin ML, Couto MDC, Casanova M, Arnao M, Perez-Persona E, Garzon S, Gonzalez MS, Martin-Sanchez G, Ocio EM, Coleman M, Encinas C, Vale AM, Teruel AI, Cortes-Rodriguez M, Paiva B, Cedena MT, San-Miguel JF, Lahuerta JJ, Blade J, Niesvizky R, Mateos MV. Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial. Blood Cancer J. 2021 May 21;11(5):101. doi: 10.1038/s41408-021-00490-8. PubMed PMID: 34021118; PubMed Central PMCID: PMC8139975.
AÑO: 2021; IF: 9.812
|
|
Bravo-Perez C, Fernandez-Caballero M, Soler-Espejo E, Garcia-Torralba E, Sorigue M, Garcia-Malo MD, Jerez A, Vicente V, Roldan V, de Arriba F. Heparin versus aspirin thromboprophylaxis adds independent value to IMPEDE-VTE score for venous thrombosis prediction in multiple myeloma. J Thromb Thrombolysis. 2021 Oct;52(3):848-853. doi: 10.1007/s11239-021-02407-5. Epub 2021 Mar 1. PubMed PMID: 33649980.
AÑO: 2021; IF: 5.221
|
|
Maia C, Puig N, Cedena MT, Goicoechea I, Valdes-Mas R, Vazquez I, Chillon MC, Aguirre P, Sarvide S, Gracia-Aznarez FJ, Alkorta G, Calasanz MJ, Garcia-Sanz R, Gonzalez M, Gutierrez NC, Martinez-Lopez J, Perez JJ, Merino J, Moreno C, Burgos L, Alignani D, Botta C, Prosper F, Matarraz S, Orfao A, Oriol A, Teruel AI, de Paz R, de Arriba F, Hernandez MT, Palomera L, Martinez R, Rosinol L, Mateos MV, Lahuerta JJ, Blade J, San Miguel JF, Paiva B. Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma. Blood. 2020 Jun 25;135(26):2375-2387. doi: 10.1182/blood.2019003382. PubMed PMID: 32299093.
AÑO: 2020; IF: 22.113
|